Navigation Links
Bleeding, not inflammation, is major cause of early lung infection death
Date:8/27/2007

lockage of blood flow, or a protective mechanism that prevents unchecked bleeding, all depending on a careful balance.

Specifically, the ability of blood to clot is increased by one regulatory pathway of reactions that end with the activation of a protein called plasminogen activator 1 (PAI-1). Against the pro-clotting influence of PAI-1 is balanced the action of another protein, cylindromatosis (CYLD), which blocks the clotting pathway just enough to keep blood flowing under normal circumstances. What Li and colleagues found is that the S. pneumoniae bacteria release a protein called pneumolysin, which causes an overproduction of CYLD, which increases the permeability of the lungs blood vessels and causes them to leak blood. They also found that pneumolysin directly increases the permeability of the lungs blood vessels, which causes yet more bleeding. Furthermore, antibiotic drugs kill bacteria by cutting them open, which releases of even more pneumolysin.

Lis team found for the first time that too much CYLD inhibits a signaling molecule (p38 kinase), which leads to reduced expression of PAI-1 expression in lung. To prove the point further, Lis team genetically engineered mice that do not have CYLD, and found that very few die of S. pnuemoniae infection.

The most immediate implication of this work is that we could make purified, recombinant PAI-1 and inject it directly into the lungs of these patients, and it would have a benefit, Li said. The next step will be to design a small molecule, a protein fragment, that can mimic PAI-1, which would be easier to deliver in the lungs, more effective and have fewer side effects. It would be even better if we could design an aerosol form, so you could just spray it into the air around these patients and their bleeding would stop.


'/>"/>
Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Researchers uncover sequence of major rice pathogen
3. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
4. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
5. Virologists make major step towards understanding the process of HIV infection
6. Major new UNC-based drinking water study suggests pregnancy fears may be overstated
7. Major breakthrough in the treatment of cancers and infectious diseases
8. Major advance made on DNA structure
9. Major link in brain-obesity puzzle found
10. Biota makes major antiviral discovery
11. New gene scanning technology marks a major advance in disease research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Vermicompost from pig manure grows healthy hibiscus 2'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Study reveals H1N1 unexpected weakness 2Advanced targeted therapies effective as first line treatment for lung cancer 53419 1Advanced targeted therapies effective as first line treatment for lung cancer 53419 2Advanced targeted therapies effective as first line treatment for lung cancer 53419 3Advanced targeted therapies effective as first line treatment for lung cancer 53419 4Advanced targeted therapies effective as first line treatment for lung cancer 53419 5Advanced targeted therapies effective as first line treatment for lung cancer 53419 6Advanced targeted therapies effective as first line treatment for lung cancer 53419 7Advanced targeted therapies effective as first line treatment for lung cancer 53419 8Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 1Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 3Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 1Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 2Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 3
Other Biology Technology:Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 2Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3